These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27177945)

  • 21. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
    Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.
    Miyata T; Minamihata K; Kurihara K; Kamizuru Y; Gotanda M; Obayashi M; Kitagawa T; Sato K; Kimura M; Oyama K; Ikeda Y; Tamaki Y; Lee JM; Sakao K; Hamanaka D; Kusakabe T; Tachibana M; Ibrahim HR
    Protein Expr Purif; 2022 Aug; 195-196():106096. PubMed ID: 35460871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Ikehara A; Tachibana M; Torii M; Matsuzaki G; Arakawa T
    Infect Immun; 2011 Oct; 79(10):4260-75. PubMed ID: 21807905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
    Atcheson E; Bauza K; Salman AM; Alves E; Blight J; Viveros-Sandoval ME; Janse CJ; Khan SM; Hill AVS; Reyes-Sandoval A
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
    Bai J; Liu F; Yang F; Zhao Y; Jia X; Thongpoon S; Roobsoog W; Sattabongkot J; Zheng L; Cui Z; Zheng W; Cui L; Cao Y
    Vaccine; 2023 Jan; 41(2):555-563. PubMed ID: 36503858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China.
    Wang S; Tian P; Li S; Liu H; Guo X; Huang F
    BMC Infect Dis; 2022 Dec; 22(1):944. PubMed ID: 36527077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
    Bouillet LÉ; Dias MO; Dorigo NA; Moura AD; Russell B; Nosten F; Renia L; Braga EM; Gazzinelli RT; Rodrigues MM; Soares IS; Bruna-Romero O
    Infect Immun; 2011 Sep; 79(9):3642-52. PubMed ID: 21730090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M; Solarte Y; Yasnot MF; Castellanos A; Rincón A; Saul A; Mu J; Long C; Miller L; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):32-7. PubMed ID: 16291764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity.
    Sala KA; Angrisano F; Da DF; Taylor IJ; Churcher TS; Blagborough AM
    Sci Rep; 2018 Jan; 8(1):1573. PubMed ID: 29371619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein.
    Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R
    Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transmission-blocking vaccine of vivax malaria.
    Tsuboi T; Tachibana M; Kaneko O; Torii M
    Parasitol Int; 2003 Mar; 52(1):1-11. PubMed ID: 12543142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.